Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Pliant Therapeutics, Inc. (PLRX)
USD1.12
+0.03 (+2.29%)
US NASDAQ Healthcare Biotechnology
Address
260 Littlefield Avenue 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
Bernard Coulie
Website
pliantrx.com
IPO
2020-06-03
CIK 1746473 ISIN US7291391057
Description
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.12
+0.03 (+2.29%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
468.2K
Beta
1.21
Float Shares
60.23M
Free Float %
97.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.67% | -5.60% | -9.23% | +6.31% | -31.40% | -3.28% | -14.49% | -94.72% | -95.97% | -94.46% | -94.46% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (16 ratings, all time)
Buy
Price Targets & DCF
Current price
1.12
Low
3.00
+169.1%
Consensus
3.00
+169.1%
Median
3.00
+169.1%
High
3.00
+169.1%
DCF (Unlevered)
0.27
-75.7%
DCF (Levered)
0.27
-76.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
17% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 4 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
3.00
+169.1%
|
| Last Year | 1 |
3.00
+169.1%
|
| All Time | 11 |
29.27
+2,525.1%
|
Quality scores
Altman Z-Score
-5.81
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+30.0% ★ Q1'26: +65.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-774.9% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.4% ★ Q1'26: +0.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.20× Q1'26: -0.33× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 4 EPS Ana. |
Dec 2027 6 Rev. Ana. 4 EPS Ana. |
Dec 2028 5 Rev. Ana. 4 EPS Ana. |
Dec 2029 2 Rev. Ana. 2 EPS Ana. |
Dec 2030 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
41.82M
est: 39.43M (+6.0%)
|
7.57M
est: 7.72M (-2.0%)
|
9.69M
est: 8.99M (+7.7%)
|
1.58M
est: 248.0K (+537.1%)
|
—
est: 90.9K (-100.0%)
|
—
est: 3.33M (-100.0%)
|
2.50M
2.50M – 2.50M
-25.0% YoY
|
5.00M
5.00M – 5.00M
+100.0% YoY
|
25.00M
25.00M – 25.00M
+400.0% YoY
|
15.00M
15.00M – 15.00M
-40.0% YoY
|
107.50M
107.50M – 107.50M
+616.7% YoY
|
| EBITDA |
-40.34M
est: -23.38M (-72.5%)
|
-95.73M
est: -94.96M (-0.8%)
|
-118.85M
est: -103.22M (-15.1%)
|
-158.23M
est: -49.6K (-318,914.5%)
|
-205.16M
est: -18.2K (-1,128,303.3%)
|
-148.38M
est: -666.7K (-22,156.6%)
|
-500.0K
-500.0K – -500.0K
+25.0% YoY
|
-1,000.0K
-1,000.0K – -1,000.0K
-100.0% YoY
|
-5.00M
-5.00M – -5.00M
-400.0% YoY
|
-3.00M
-3.00M – -3.00M
+40.0% YoY
|
-21.50M
-21.50M – -21.50M
-616.7% YoY
|
| EBIT |
-41.65M
est: -23.63M (-76.3%)
|
-97.26M
est: -97.07M (-0.2%)
|
-122.53M
est: -105.70M (-15.9%)
|
-160.07M
est: -49.6K (-322,626.3%)
|
-207.28M
est: -18.2K (-1,139,991.3%)
|
-150.07M
est: -666.7K (-22,411.0%)
|
-500.0K
-500.0K – -500.0K
+25.0% YoY
|
-1,000.0K
-1,000.0K – -1,000.0K
-100.0% YoY
|
-5.00M
-5.00M – -5.00M
-400.0% YoY
|
-3.00M
-3.00M – -3.00M
+40.0% YoY
|
-21.50M
-21.50M – -21.50M
-616.7% YoY
|
| Net Income |
-41.53M
est: -131.15M (+68.3%)
|
-97.26M
est: -96.80M (-0.5%)
|
-123.32M
est: -144.42M (+14.6%)
|
-161.34M
est: -189.48M (+14.9%)
|
-210.30M
est: -218.38M (+3.7%)
|
-149.34M
est: -149.34M (+0.0%)
|
-94.31M
-105.95M – -73.81M
+36.9% YoY
|
-78.73M
-86.85M – -56.43M
+16.5% YoY
|
-62.91M
-111.11M – -14.71M
+20.1% YoY
|
-68.12M
-68.12M – -68.12M
-8.3% YoY
|
-48.48M
-48.48M – -48.48M
+28.8% YoY
|
| SGA |
17.27M
est: 361.53M (-95.2%)
|
27.56M
est: -33.40M (+182.5%)
|
39.95M
est: -25.65M (+255.7%)
|
57.93M
est: 2.30M (+2,415.5%)
|
59.06M
est: 844.1K (+6,895.9%)
|
47.22M
est: 30.95M (+52.5%)
|
23.21M
23.21M – 23.21M
-25.0% YoY
|
46.43M
46.43M – 46.43M
+100.0% YoY
|
232.14M
232.14M – 232.14M
+400.0% YoY
|
139.28M
139.28M – 139.28M
-40.0% YoY
|
998.19M
998.19M – 998.19M
+616.7% YoY
|
| EPS |
-1.17
est: -2.17 (+46.0%)
|
-2.71
est: -2.79 (+3.0%)
|
-2.94
est: -2.89 (-1.6%)
|
-2.75
est: -3.09 (+10.9%)
|
-3.47
est: -3.56 (+2.6%)
|
-2.43
est: -2.43 (-0.2%)
|
-1.46
-1.73 – -1.20
+39.6% YoY
|
-1.10
-1.42 – -0.92
+24.7% YoY
|
-0.97
-1.81 – -0.24
+12.4% YoY
|
-1.11
-1.11 – -1.11
-15.0% YoY
|
-0.79
-0.79 – -0.79
+28.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-98.70M
OE per share TTM
-1.61
Owner's Yield
-133.08%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
78.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
7
Total invested
1.76M
Insider transactions (90d)
4
Beneficial owners (>5%)
32
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kevin P. Starr | 5.84M | 16.50% | — | 5.84M | — | 5.84M | IN | Delaware | 2021-02-16 | ↗ |
| 2 | Mark Levin | 5.84M | 16.50% | — | 5.84M | — | 5.84M | IN | Delaware | 2021-02-16 | ↗ |
| 3 | Robert I. Tepper | 5.84M | 16.50% | — | 5.84M | — | 5.84M | IN | Delaware | 2021-02-16 | ↗ |
| 4 | TRV GP III, LLC | 5.84M | 16.50% | — | 5.84M | — | 5.84M | OO | Delaware | 2021-02-16 | ↗ |
| 5 | Third Rock Ventures GP III, L.P. | 5.84M | 16.50% | — | 5.84M | — | 5.84M | PN | Delaware | 2021-02-16 | ↗ |
| 6 | Third Rock Ventures III, L.P. | 5.84M | 16.50% | — | 5.84M | — | 5.84M | PN | Delaware | 2021-02-16 | ↗ |
| 7 | Abigail P. Johnson | 5.33M | 15.00% | — | — | 5.33M | — | IN | Delaware | 2020-07-10 | ↗ |
| 8 | FMR LLC | 5.33M | 15.00% | 697.9K | — | 5.33M | — | HC | Delaware | 2020-07-10 | ↗ |
| 9 | (1) BlackRock, Inc. | 4.80M | 8.00% | 4.74M | — | 4.80M | — | HC | Delaware | 2024-01-25 | ↗ |
| 10 | 52-0556948 | 3.79M | 6.30% | 791.2K | — | 3.79M | — | IA | Maryland | 2024-02-14 | ↗ |
| 11 | Mathew P. Arens | 3.68M | 6.14% | 2.0K | 3.68M | 2.0K | — | IN | Delaware | 2024-02-14 | ↗ |
| 12 | First Light Asset Management, LLC | 3.63M | 6.07% | — | 3.63M | — | — | IA | Delaware | 2024-02-14 | ↗ |
| 13 | Benjamin Alexander Smith | 3.58M | 5.98% | — | 3.58M | — | — | IN | United States | 2024-02-08 | ↗ |
| 14 | Janaka Sheehan Maduraperuma | 3.58M | 5.98% | — | 3.58M | — | — | IN | United Kingdom | 2024-02-08 | ↗ |
| 15 | Laurion Capital Management LP | 3.58M | 5.98% | — | 3.58M | — | — | IA, PN | Delaware | 2024-02-08 | ↗ |
| 16 | Jeremy C. Green | 3.20M | 5.30% | — | 3.20M | — | 3.20M | HC, IN | Delaware | 2024-11-14 | ↗ |
| 17 | Redmile Group, LLC | 3.20M | 5.30% | — | 3.20M | — | 3.20M | IA, OO | Delaware | 2024-11-14 | ↗ |
| 18 | David Kroin | 3.10M | 5.27% | — | 3.10M | — | — | HC, IN | Delaware | 2023-03-20 | ↗ |
| 19 | Deep Track Biotechnology Master Fund, Ltd. | 3.10M | 5.27% | — | 3.10M | — | — | CO | Delaware | 2023-03-20 | ↗ |
| 20 | Deep Track Capital, LP | 3.10M | 5.27% | — | 3.10M | — | — | IA, OO | Delaware | 2023-03-20 | ↗ |
| 21 | Blue Owl Capital Holdings LP | 3.00M | 5.02% | 3.00M | — | 3.00M | — | PN | Delaware | 2024-02-14 | ↗ |
| 22 | CHI Advisors LLC | 2.35M | 6.60% | 2.35M | — | 2.35M | — | IA | Delaware | 2021-03-02 | ↗ |
| 23 | 2. | 2.15M | 6.10% | — | 2.15M | — | 2.15M | CO | — | 2020-06-15 | ↗ |
| 24 | Novartis AG | 2.15M | 4.40% | — | 2.15M | — | 2.15M | HC, CO | Delaware | 2022-08-31 | ↗ |
| 25 | Novartis Institutes for BioMedical Research, Inc. | 2.15M | 4.40% | — | 2.15M | — | 2.15M | CO | Delaware | 2022-08-31 | ↗ |
| 26 | TRV GP IV, LLC | 2.13M | 6.00% | — | 2.13M | — | 2.13M | OO | Delaware | 2021-02-16 | ↗ |
| 27 | Third Rock Ventures GP IV, L.P. | 2.13M | 6.00% | — | 2.13M | — | 2.13M | PN | Delaware | 2021-02-16 | ↗ |
| 28 | Third Rock Ventures IV, L.P. | 2.13M | 6.00% | — | 2.13M | — | 2.13M | PN | Delaware | 2021-02-16 | ↗ |
| 29 | Redmile Biopharma Investments II, L.P. | 1.91M | 5.30% | — | 1.91M | — | 1.91M | PN | — | 2022-02-14 | ↗ |
| 30 | Eventide Asset Management, LLC | 42.5K | 0.10% | 42.5K | — | 42.5K | — | IA | Delaware | 2022-02-14 | ↗ |
| 31 | Finny Kuruvilla, M.D. Ph. D. | 42.5K | 0.10% | — | 42.5K | — | — | HC, IN | United States | 2022-02-14 | ↗ |
| 32 | Robin C. John | 42.5K | 0.10% | — | 42.5K | — | — | HC, IN | United States | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
7
-92 vs prev Q
New positions
1
Closed positions
89
Increased
3
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | NANO CAP NEW MILLENNIUM GROWTH FUND L P | 235.0K +235.0K (+100.0%) | 286.70M +286.7M (+100.0%) | 0.38% +0.383 pp | 0.24% +0.245 pp | USD1.22 +0.0% | 1 qtrs NEW |
| 2 | TANG CAPITAL MANAGEMENT LLC | 6.14M +139.7K (+2.3%) | 7.49M -1.4M (-15.6%) | 10.00% +0.224 pp | 0.37% +0.028 pp | USD1.35 -9.6% | 4 qtrs — |
| 3 | BLUE OWL CAPITAL HOLDINGS LP | 2.97M +— (+0.0%) | 3.62M -772.0K (-17.6%) | 4.84% -0.002 pp | 0.27% -1.093 pp | USD16.98 -92.8% | 9 qtrs — |
| 4 | VANGUARD GROUP INC | 2.82M +42.3K (+1.5%) | 3.44M -670.1K (-16.3%) | 4.59% +0.067 pp | 0.00% +0.000 pp | USD21.52 -94.3% | 23 qtrs — |
| 5 | CITADEL ADVISORS LLC | 2.58M +243.9K (+10.4%) | 3.15M -310.7K (-9.0%) | 4.21% +0.396 pp | 0.00% 0.000 pp | USD1.17 +4.3% | 23 qtrs — |
| 6 | ACADIAN ASSET MANAGEMENT LLC | 2.36M -4.9K (-0.2%) | 2.88M -622.0K (-17.8%) | 3.85% -0.009 pp | 0.00% -0.001 pp | USD1.36 -10.3% | 4 qtrs — |
| 7 | WOODLINE PARTNERS LP | 2.03M -2.5M (-55.0%) | 2.47M -4.2M (-62.9%) | 3.30% -4.039 pp | 0.01% -0.022 pp | USD1.82 -33.0% | 11 qtrs — |
| 8 | MONACO ASSET MANAGEMENT SAM | 1.94M +1.1M (+135.7%) | 2.37M +1.1M (+94.3%) | 3.16% +1.817 pp | 0.41% +0.336 pp | USD1.21 +0.8% | 3 qtrs — |
| 9 | REDMILE GROUP, LLC | 1.62M +24.5K (+1.5%) | 1.97M -383.9K (-16.3%) | 2.63% +0.039 pp | 0.15% -0.084 pp | USD25.95 -95.3% | 23 qtrs — |
| 10 | PROSIGHT MANAGEMENT, LP | 1.56M +1.5M (+7,493.8%) | 1.90M +1.9M (+6,159.7%) | 2.53% +2.500 pp | 0.39% +0.385 pp | USD1.22 +0.0% | 4 qtrs — |
| 11 | BML CAPITAL MANAGEMENT, LLC | 1.55M +1.5M (+100.0%) | 1.89M +1.9M (+100.0%) | 2.52% +2.518 pp | 1.63% +1.631 pp | USD1.22 +0.0% | 1 qtrs NEW |
| 12 | TWO SIGMA ADVISERS, LP | 1.25M +173.1K (+16.1%) | 1.52M -67.7K (-4.3%) | 2.03% +0.281 pp | 0.00% 0.000 pp | USD3.05 -60.0% | 17 qtrs — |
| 13 | JPMORGAN CHASE & CO | 1.21M -917.6K (-43.1%) | 1.48M -1.7M (-53.1%) | 1.98% -1.496 pp | 0.00% 0.000 pp | USD2.46 -50.4% | 22 qtrs — |
| 14 | MARSHALL WACE, LLP | 1.08M +780.7K (+260.7%) | 1.32M +874.6K (+197.3%) | 1.76% +1.271 pp | 0.00% +0.001 pp | USD1.29 -5.4% | 5 qtrs — |
| 15 | BLACKROCK, INC. | 1.07M -347.6K (-24.5%) | 1.31M -793.5K (-37.7%) | 1.75% -0.567 pp | 0.00% +0.000 pp | USD11.09 -89.0% | 6 qtrs — |
| 16 | UBS GROUP AG | 1.06M -259.4K (-19.6%) | 1.30M -660.2K (-33.7%) | 1.73% -0.423 pp | 0.00% 0.000 pp | USD4.34 -71.9% | 22 qtrs — |
| 17 | RENAISSANCE TECHNOLOGIES LLC | 1.05M +34.0K (+3.4%) | 1.28M -221.6K (-14.8%) | 1.70% +0.055 pp | 0.00% +0.000 pp | USD1.72 -29.1% | 8 qtrs — |
| 18 | CENTIVA CAPITAL, LP | 1.00M +1.0M (+100.0%) | 1.22M +1.2M (+100.0%) | 1.63% +1.629 pp | 0.01% +0.010 pp | USD1.22 +0.0% | 1 qtrs NEW |
| 19 | TWO SIGMA INVESTMENTS, LP | 953.3K +170.0K (+21.7%) | 1.16M +3.8K (+0.3%) | 1.55% +0.277 pp | 0.00% 0.000 pp | USD2.54 -52.0% | 17 qtrs — |
| 20 | PEAPOD LANE CAPITAL LLC | 886.4K -210.7K (-19.2%) | 1.08M -542.2K (-33.4%) | 1.44% -0.344 pp | 0.92% -0.532 pp | USD1.33 -8.3% | 4 qtrs — |
| 21 | EVERSEPT PARTNERS, LP | 842.0K +17.4K (+2.1%) | 1.03M -193.1K (-15.8%) | 1.37% +0.028 pp | 0.05% -0.032 pp | USD1.47 -17.0% | 2 qtrs — |
| 22 | BANK OF AMERICA CORP /DE/ | 711.8K +3.7K (+0.5%) | 868.4K -179.6K (-17.1%) | 1.16% +0.006 pp | 0.00% +0.000 pp | USD2.58 -52.7% | 22 qtrs — |
| 23 | JANE STREET GROUP, LLC | 653.8K +273.4K (+71.9%) | 797.6K +234.7K (+41.7%) | 1.06% +0.445 pp | 0.00% +0.000 pp | USD4.09 -70.2% | 13 qtrs — |
| 24 | GSA CAPITAL PARTNERS LLP | 623.7K +462.8K (+287.7%) | 761.0K +523.0K (+219.7%) | 1.02% +0.754 pp | 0.07% +0.046 pp | USD1.28 -4.7% | 4 qtrs — |
| 25 | GEODE CAPITAL MANAGEMENT, LLC | 592.7K +5.3K (+0.9%) | 723.4K -146.4K (-16.8%) | 0.97% +0.008 pp | 0.00% +0.000 pp | USD18.70 -93.5% | 23 qtrs — |
| 26 | JACOBS LEVY EQUITY MANAGEMENT, INC | 556.9K +189.8K (+51.7%) | 679.5K +136.1K (+25.1%) | 0.91% +0.309 pp | 0.00% +0.001 pp | USD1.39 -12.2% | 2 qtrs — |
| 27 | MORGAN STANLEY | 549.0K -3.0M (-84.3%) | 669.7K -4.5M (-87.1%) | 0.89% -4.820 pp | 0.00% 0.000 pp | USD4.10 -70.2% | 23 qtrs — |
| 28 | XTX TOPCO LTD | 545.0K +78.0K (+16.7%) | 664.9K -26.2K (-3.8%) | 0.89% +0.127 pp | 0.02% -0.018 pp | USD1.34 -9.0% | 4 qtrs — |
| 29 | BESSEMER GROUP INC | 532.1K +— (+0.0%) | 649.0K -138.0K (-17.5%) | 0.87% 0.000 pp | 0.00% 0.000 pp | USD31.41 -96.1% | 23 qtrs — |
| 30 | DEKABANK DEUTSCHE GIROZENTRALE | 40.0K +— (+0.0%) | 633.0K +576.0K (+1,010.5%) | 0.07% +0.000 pp | 0.00% +0.001 pp | USD24.48 -95.0% | 12 qtrs — |
| 31 | MILLENNIUM MANAGEMENT LLC | 408.8K -128.5K (-23.9%) | 498.8K -296.5K (-37.3%) | 0.67% -0.210 pp | 0.00% 0.000 pp | USD1.16 +5.2% | 3 qtrs — |
| 32 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 372.0K +347.6K (+1,428.1%) | 453.8K +417.8K (+1,159.7%) | 0.61% +0.566 pp | 0.00% +0.001 pp | USD1.24 -1.6% | 2 qtrs — |
| 33 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 321.5K +239.2K (+290.7%) | 392.3K +270.5K (+222.0%) | 0.52% +0.390 pp | 0.01% +0.006 pp | USD1.20 +1.7% | 3 qtrs — |
| 34 | TORNO CAPITAL, LLC | 320.0K +189.1K (+144.4%) | 390.4K +196.6K (+101.5%) | 0.52% +0.308 pp | 0.09% +0.071 pp | USD1.33 -8.3% | 2 qtrs — |
| 35 | SEI INVESTMENTS CO | 297.3K +— (+0.0%) | 362.7K -77.3K (-17.6%) | 0.48% 0.000 pp | 0.00% 0.000 pp | USD1.32 -7.6% | 4 qtrs — |
| 36 | ARROWMARK COLORADO HOLDINGS LLC | 281.2K +— (+0.0%) | 343.1K -73.1K (-17.6%) | 0.46% 0.000 pp | 0.01% 0.000 pp | USD18.12 -93.3% | 11 qtrs — |
| 37 | GOLDMAN SACHS GROUP INC | 276.9K -278.2K (-50.1%) | 337.8K -483.7K (-58.9%) | 0.45% -0.453 pp | 0.00% 0.000 pp | USD11.30 -89.2% | 23 qtrs — |
| 38 | — | 276.5K +276.5K (+100.0%) | 337.3K +337.3K (+100.0%) | 0.45% +0.450 pp | 0.26% +0.257 pp | USD1.22 +0.0% | 1 qtrs NEW |
| 39 | LAURION CAPITAL MANAGEMENT LP | 257.4K +257.4K (+100.0%) | 314.0K +314.0K (+100.0%) | 0.42% +0.419 pp | 0.01% +0.012 pp | USD1.22 +0.0% | 1 qtrs NEW |
| 40 | STATE STREET CORP | 253.4K -416.0 (-0.2%) | 309.2K -66.5K (-17.7%) | 0.41% -0.001 pp | 0.00% +0.000 pp | USD18.76 -93.5% | 22 qtrs — |
| 41 | STONEPINE CAPITAL MANAGEMENT, LLC | 230.1K -59.2K (-20.5%) | 280.7K -147.4K (-34.4%) | 0.37% -0.097 pp | 0.20% -0.143 pp | USD1.48 -17.6% | 2 qtrs — |
| 42 | RANGELEY CAPITAL, LLC | 225.0K +164.8K (+273.6%) | 274.5K +185.4K (+208.0%) | 0.37% +0.268 pp | 0.23% +0.151 pp | USD1.25 -2.4% | 4 qtrs — |
| 43 | HIGHMARK WEALTH MANAGEMENT LLC | 170.9K -48.1K (-22.0%) | 208.5K -115.6K (-35.7%) | 0.28% -0.078 pp | 0.09% -0.058 pp | USD5.39 -77.4% | 9 qtrs — |
| 44 | RICE HALL JAMES & ASSOCIATES, LLC | 147.7K +2.9K (+2.0%) | 180.2K -34.2K (-15.9%) | 0.24% +0.005 pp | 0.01% -0.002 pp | USD10.29 -88.1% | 7 qtrs — |
| 45 | DIADEMA PARTNERS LP | 144.9K +144.9K (+100.0%) | 176.8K +176.8K (+100.0%) | 0.24% +0.236 pp | 0.03% +0.031 pp | USD1.22 +0.0% | 1 qtrs NEW |
| 46 | NORTHERN TRUST CORP | 123.3K -13.2K (-9.7%) | 150.4K -51.6K (-25.6%) | 0.20% -0.022 pp | 0.00% +0.000 pp | USD18.50 -93.4% | 22 qtrs — |
| 47 | DIMENSIONAL FUND ADVISORS LP | 121.8K -29.9K (-19.7%) | 148.5K -76.0K (-33.9%) | 0.20% -0.049 pp | 0.00% +0.000 pp | USD14.72 -91.7% | 16 qtrs — |
| 48 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 115.3K +58.8K (+104.1%) | 140.7K +57.0K (+68.2%) | 0.19% +0.096 pp | 0.00% +0.000 pp | USD5.67 -78.5% | 17 qtrs — |
| 49 | ADVISOR GROUP HOLDINGS, INC. | 115.0K -10.4K (-8.3%) | 140.3K -45.4K (-24.4%) | 0.19% -0.017 pp | 0.00% 0.000 pp | USD1.95 -37.4% | 14 qtrs — |
| 50 | INVESCO LTD. | 113.9K +6.8K (+6.4%) | 139.0K -19.5K (-12.3%) | 0.19% +0.011 pp | 0.00% +0.000 pp | USD7.81 -84.4% | 11 qtrs — |
| 51 | HENNION & WALSH ASSET MANAGEMENT, INC. | 113.4K +15.3K (+15.7%) | 138.3K -6.8K (-4.7%) | 0.18% +0.025 pp | 0.00% -0.001 pp | USD9.93 -87.7% | 7 qtrs — |
| 52 | BOND & DEVICK FINANCIAL NETWORK, INC. | 100.2K +— (+0.0%) | 122.2K -26.0K (-17.6%) | 0.16% 0.000 pp | 0.03% -0.010 pp | USD29.12 -95.8% | 19 qtrs — |
| 53 | SQUAREPOINT OPS LLC | 99.0K +65.2K (+192.6%) | 120.8K +70.7K (+141.2%) | 0.16% +0.106 pp | 0.00% +0.000 pp | USD1.75 -30.3% | 7 qtrs — |
| 54 | QUADRATURE CAPITAL LTD | 97.9K +60.3K (+160.4%) | 119.4K +64.0K (+115.4%) | 0.16% +0.098 pp | 0.00% +0.001 pp | USD1.27 -3.9% | 4 qtrs — |
| 55 | KOTLER KEVIN | 93.0K +93.0K (+100.0%) | 113.5K +113.5K (+100.0%) | 0.15% +0.151 pp | 0.03% +0.027 pp | USD1.22 +0.0% | 1 qtrs NEW |
| 56 | ALGERT GLOBAL LLC | 84.5K -19.9K (-19.1%) | 103.0K -51.0K (-33.1%) | 0.14% -0.033 pp | 0.00% -0.001 pp | USD10.54 -88.4% | 12 qtrs — |
| 57 | ADAR1 CAPITAL MANAGEMENT, LLC | 73.8K +73.8K (+100.0%) | 90.1K +90.1K (+100.0%) | 0.12% +0.120 pp | 0.01% +0.007 pp | USD1.22 +0.0% | 7 qtrs — |
| 58 | CANADA PENSION PLAN INVESTMENT BOARD | 61.4K +61.4K (+100.0%) | 74.9K +74.9K (+100.0%) | 0.10% +0.100 pp | 0.00% +0.000 pp | USD1.22 +0.0% | 3 qtrs — |
| 59 | FEDERATED HERMES, INC. | 59.5K +4.2K (+7.6%) | 72.6K -9.3K (-11.3%) | 0.10% +0.007 pp | 0.00% +0.000 pp | USD1.70 -28.2% | 6 qtrs — |
| 60 | POINT72 ASSET MANAGEMENT, L.P. | 46.5K -4.3M (-98.9%) | 56.8K -6.4M (-99.1%) | 0.08% -6.992 pp | 0.00% -0.011 pp | USD1.48 -17.6% | 2 qtrs — |
| 61 | SIMPLEX TRADING, LLC | 45.9K +32.9K (+253.5%) | 56.0K +37.0K (+194.8%) | 0.07% +0.054 pp | 0.00% +0.000 pp | USD2.48 -50.8% | 15 qtrs — |
| 62 | PERSISTENT ASSET PARTNERS LTD | 38.8K +38.8K (+100.0%) | 47.4K +47.4K (+100.0%) | 0.06% +0.063 pp | 0.02% +0.021 pp | USD1.22 +0.0% | 1 qtrs NEW |
| 63 | HRT FINANCIAL LP | 32.2K +32.2K (+100.0%) | 39.0K +39.0K (+100.0%) | 0.05% +0.052 pp | 0.00% +0.000 pp | USD1.22 +0.0% | 3 qtrs — |
| 64 | ENGINEERS GATE MANAGER LP | 30.5K +7.1K (+30.0%) | 37.3K +2.5K (+7.2%) | 0.05% +0.012 pp | 0.00% +0.000 pp | USD1.23 -0.8% | 6 qtrs — |
| 65 | TUDOR INVESTMENT CORP ET AL | 29.7K +— (+0.0%) | 36.3K -7.7K (-17.6%) | 0.05% +0.000 pp | 0.00% +0.000 pp | USD1.35 -9.6% | 8 qtrs — |
| 66 | VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 26.2K -8.5K (-24.5%) | 32.0K -19.4K (-37.7%) | 0.04% -0.014 pp | 0.00% 0.000 pp | USD1.25 -2.4% | 4 qtrs — |
| 67 | BLACKSTONE INC. | 22.2K +— (+0.0%) | 27.1K -5.8K (-17.6%) | 0.04% +0.000 pp | 0.00% +0.000 pp | USD19.71 -93.8% | 14 qtrs — |
| 68 | BRONTE CAPITAL MANAGEMENT PTY LTD. | 18.6K +18.6K (+100.0%) | 22.7K +22.7K (+100.0%) | 0.03% +0.030 pp | 0.00% +0.002 pp | USD1.22 +0.0% | 1 qtrs NEW |
| 69 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 18.1K +— (+0.0%) | 22.0K -4.7K (-17.6%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD1.35 -9.6% | 4 qtrs — |
| 70 | BANK OF NEW YORK MELLON CORP | 15.8K -109.0 (-0.7%) | 19.3K -4.3K (-18.1%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD17.81 -93.1% | 23 qtrs — |
| 71 | GROUP ONE TRADING, L.P. | 15.8K +12.7K (+405.9%) | 19.3K +14.6K (+317.1%) | 0.03% +0.021 pp | 0.00% +0.000 pp | USD4.35 -72.0% | 12 qtrs — |
| 72 | QUBE RESEARCH & TECHNOLOGIES LTD | 15.4K -34.1K (-68.8%) | 18.8K -54.5K (-74.3%) | 0.03% -0.056 pp | 0.00% 0.000 pp | USD1.16 +5.2% | 3 qtrs — |
| 73 | SG AMERICAS SECURITIES, LLC | 12.3K -4.5K (-26.9%) | 15.0K -10.0K (-40.0%) | 0.02% -0.007 pp | 0.00% 0.000 pp | USD9.28 -86.9% | 8 qtrs — |
| 74 | QUEST PARTNERS LLC | 11.7K +— (+0.0%) | 14.3K -3.0K (-17.6%) | 0.02% +0.000 pp | 0.00% 0.000 pp | USD8.17 -85.1% | 9 qtrs — |
| 75 | FIDUCIARY TRUST CO | 11.6K +— (+0.0%) | 14.2K -3.0K (-17.6%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD18.95 -93.6% | 13 qtrs — |
| 76 | BARCLAYS PLC | 10.6K -410.9K (-97.5%) | 12.9K -4.7M (-99.7%) | 0.02% -0.669 pp | 0.00% -0.001 pp | USD1.94 -37.1% | 16 qtrs — |
| 77 | RHUMBLINE ADVISERS | 2.4K +— (+0.0%) | 2.9K -618.0 (-17.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD16.97 -92.8% | 11 qtrs — |
| 78 | FMR LLC | 1.9K -3.0K (-61.1%) | 2.4K -5.0K (-67.9%) | 0.00% -0.005 pp | 0.00% +0.000 pp | USD27.20 -95.5% | 23 qtrs — |
| 79 | ROYAL BANK OF CANADA | 1.2K -15.0K (-92.7%) | 2.0K -22.0K (-91.7%) | 0.00% -0.024 pp | 0.00% +0.000 pp | USD5.81 -79.0% | 21 qtrs — |
| 80 | FORTITUDE FAMILY OFFICE, LLC | 1.3K +— (+0.0%) | 1.6K -332.0 (-17.6%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD1.48 -17.6% | 2 qtrs — |
| 81 | PNC FINANCIAL SERVICES GROUP, INC. | 978.00 -6.0 (-0.6%) | 1.2K -263.0 (-18.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.40 -49.2% | 12 qtrs — |
| 82 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 660.00 -425.0 (-39.2%) | 805.00 -801.0 (-49.9%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD1.48 -17.6% | 2 qtrs — |
| 83 | BNP PARIBAS ARBITRAGE, SNC | 657.00 -181.7K (-99.6%) | 802.00 -269.1K (-99.7%) | 0.00% -0.296 pp | 0.00% 0.000 pp | USD1.78 -31.5% | 5 qtrs — |
| 84 | RUSSELL INVESTMENTS GROUP, LTD. | 542.00 -864.0 (-61.5%) | 661.00 -1.4K (-68.2%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD1.97 -38.1% | 19 qtrs — |
| 85 | BARE FINANCIAL SERVICES, INC | 413.00 +413.0 (+100.0%) | 504.00 +504.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.22 +0.0% | 1 qtrs NEW |
| 86 | MAI CAPITAL MANAGEMENT | 400.00 +— (+0.0%) | 488.00 -104.0 (-17.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD13.17 -90.7% | 5 qtrs — |
| 87 | SBI SECURITIES CO., LTD. | 320.00 +— (+0.0%) | 390.00 -84.0 (-17.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.68 -73.9% | 5 qtrs — |
| 88 | TRUVESTMENTS CAPITAL LLC | 50.00 +— (+0.0%) | 61.00 -13.0 (-17.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD11.20 -89.1% | 12 qtrs — |
| 89 | WELLS FARGO & COMPANY/MN | 50.00 +— (+0.0%) | 61.00 -13.0 (-17.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD16.44 -92.6% | 22 qtrs — |
| 90 | ZURCHER KANTONALBANK (ZURICH CANTONALBANK) | 36.00 -570.0 (-94.1%) | 44.00 -853.0 (-95.1%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD16.06 -92.4% | 13 qtrs — |
| 91 | COMERICA BANK | 6.00 -8.0 (-57.1%) | 7.00 -14.0 (-66.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD17.17 -92.9% | 10 qtrs — |
| 92 | FARTHER FINANCE ADVISORS, LLC | 5.00 +— (+0.0%) | 6.00 -1.0 (-14.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD18.00 -93.2% | 9 qtrs — |
| 93 | GLOBAL RETIREMENT PARTNERS, LLC | 4.00 +— (+0.0%) | 5.00 -1.0 (-16.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.00 +22.0% | 3 qtrs — |
| 94 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 1.00 -2.0K (-100.0%) | 1.00 -3.0K (-100.0%) | 0.00% -0.003 pp | 0.00% -0.002 pp | USD1.00 +22.0% | 3 qtrs — |
| 95 | GREAT POINT PARTNERS LLC | — -850.0K (-100.0%) | — -1.3M (-100.0%) | 0.00% -1.385 pp | 0.00% -0.519 pp | USD— | 15 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 14 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.02% | 231.4K | 0.60% |
| 2 | Invesco RAFI US 1500 Small-Mid ETF PRFZ | 0.00% | 116.6K | 0.34% |
| 3 | Vanguard Health Care ETF VHT | 0.00% | 193.1K | 0.09% |
| 4 | Vanguard Extended Market ETF VXF | 0.00% | 758.4K | 0.05% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 945.84 | 0.17% |
| 6 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 4.7K | 0.03% |
| 7 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 12.8K | 0.17% |
| 8 | Vanguard Total Stock Market ETF VTI | 0.00% | 2.19M | 0.03% |
| 9 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 4.8K | 0.22% |
| 10 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 2.6K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
1.00
Neutral
Buys
20
Sells
20
Shares acquired
3.02M
Shares disposed
3.02M
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-17 | Kuo Minnie | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 1.33 | 199.5K | 150,000 | D | ↗ |
| 2026-04-17 | Cummings Keith Lamont | Officer | D-Return | D | Stock Option (Right to Buy) | 18,198 | 6.22 | 113.2K | 0 | D | ↗ |
| 2026-04-17 | Coulie Bernard | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 440,000 | 1.33 | 585.2K | 440,000 | D | ↗ |
| 2026-04-17 | Cheung Lily | Officer | A-Award | A | Stock Option (Right to Buy) | 123,000 | 1.33 | 163.6K | 123,000 | D | ↗ |
| 2026-01-22 | Kuo Minnie | Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 1.30 | 390.0K | 300,000 | D | ↗ |
| 2026-01-22 | Cummings Keith Lamont | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 1.30 | 520.0K | 400,000 | D | ↗ |
| 2026-01-22 | Coulie Bernard | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,230,000 | 1.30 | 1.60M | 1,230,000 | D | ↗ |
| 2026-01-22 | Cheung Lily | Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 1.30 | 390.0K | 300,000 | D | ↗ |
| 2026-01-20 | Kuo Minnie | Officer | S-Sale | D | Common Stock | 6,917 | 1.28 | 8.9K | 37,806 | D | ↗ |
| 2026-01-20 | Cummings Keith Lamont | Officer | S-Sale | D | Common Stock | 24,002 | 1.28 | 30.7K | 297,214 | D | ↗ |
| 2026-01-20 | Coulie Bernard | Director / Officer | S-Sale | D | Common Stock | 89,375 | 1.28 | 114.4K | 505,601 | D | ↗ |
| 2026-01-20 | Cheung Lily | Officer | S-Sale | D | Common Stock | 7,534 | 1.28 | 9.6K | 44,847 | D | ↗ |
| 2025-12-10 | Kuo Minnie | Officer | — | — | Common Stock | 0 | 0.00 | — | 44,723 | D | ↗ |
| 2025-06-05 | PYOTT DAVID E I | Director | A-Award | A | Common Stock (Right to Buy) | 30,000 | 1.61 | 48.3K | 30,000 | D | ↗ |
| 2025-06-05 | MCCOURT Thomas A | Director | A-Award | A | Common Stock (Right to Buy) | 30,000 | 1.61 | 48.3K | 30,000 | D | ↗ |
| 2025-06-05 | Krognes Steve E. | Director | A-Award | A | Common Stock (Right to Buy) | 30,000 | 1.61 | 48.3K | 30,000 | D | ↗ |
| 2025-06-05 | Knobil Katharine | Director | A-Award | A | Common Stock (Right to Buy) | 30,000 | 1.61 | 48.3K | 30,000 | D | ↗ |
| 2025-06-05 | Huh Hoyoung | Director | A-Award | A | Common Stock (Right to Buy) | 30,000 | 1.61 | 48.3K | 30,000 | D | ↗ |
| 2025-06-05 | Curnutte John T | Director | A-Award | A | Common Stock (Right to Buy) | 30,000 | 1.61 | 48.3K | 30,000 | D | ↗ |
| 2025-06-05 | Cline Darren S | Director | A-Award | A | Common Stock (Right to Buy) | 30,000 | 1.61 | 48.3K | 30,000 | D | ↗ |
| 2025-06-05 | CROWELL GAYLE A | Director | A-Award | A | Common Stock (Right to Buy) | 30,000 | 1.61 | 48.3K | 30,000 | D | ↗ |
| 2025-06-05 | Bruhn Suzanne Louise | Director | A-Award | A | Common Stock (Right to Buy) | 30,000 | 1.61 | 48.3K | 30,000 | D | ↗ |
| 2025-01-23 | Ouimette Mike | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 11.14 | 779.8K | 70,000 | D | ↗ |
| 2025-01-23 | Lefebvre Eric | Officer | A-Award | A | Stock Option (Right to Buy) | 91,300 | 11.14 | 1.02M | 91,300 | D | ↗ |
| 2025-01-23 | Hull Hans | Officer | A-Award | A | Stock Option (Right to Buy) | 80,300 | 11.14 | 894.5K | 80,300 | D | ↗ |
| 2025-01-23 | Cummings Keith Lamont | Officer | A-Award | A | Stock Option (Right to Buy) | 113,300 | 11.14 | 1.26M | 113,300 | D | ↗ |
| 2025-01-23 | Coulie Bernard | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 325,000 | 11.14 | 3.62M | 325,000 | D | ↗ |
| 2025-01-23 | Cheung Lily | Officer | A-Award | A | Common Stock | 25,875 | 0.00 | — | 50,425 | D | ↗ |
| 2025-01-22 | Ouimette Mike | Officer | S-Sale | D | Common Stock | 10,230 | 10.99 | 112.5K | 70,544 | D | ↗ |
| 2025-01-17 | Ouimette Mike | Officer | S-Sale | D | Common Stock | 13,270 | 11.20 | 148.6K | 80,774 | D | ↗ |
| 2025-01-17 | Lefebvre Eric | Officer | S-Sale | D | Common Stock | 18,478 | 11.20 | 207.0K | 194,574 | D | ↗ |
| 2025-01-17 | Hull Hans | Officer | S-Sale | D | Common Stock | 15,936 | 11.20 | 178.5K | 211,558 | D | ↗ |
| 2025-01-17 | Cummings Keith Lamont | Officer | S-Sale | D | Common Stock | 20,148 | 11.20 | 225.7K | 262,608 | D | ↗ |
| 2025-01-17 | Coulie Bernard | Director / Officer | S-Sale | D | Common Stock | 52,419 | 11.20 | 587.2K | 430,517 | D | ↗ |
| 2025-01-17 | Cheung Lily | Officer | S-Sale | D | Common Stock | 3,740 | 11.20 | 41.9K | 24,550 | D | ↗ |
| 2024-07-10 | Ouimette Mike | Officer | S-Sale | D | Common Stock | 7,656 | 11.56 | 88.5K | 94,044 | — | ↗ |
| 2024-07-10 | Lefebvre Eric | Officer | S-Sale | D | Common Stock | 12,319 | 11.56 | 142.4K | 213,052 | — | ↗ |
| 2024-07-10 | Hull Hans | Officer | S-Sale | D | Common Stock | 9,900 | 11.56 | 114.4K | 227,494 | — | ↗ |
| 2024-07-10 | Cummings Keith Lamont | Officer | S-Sale | D | Common Stock | 10,911 | 11.56 | 126.1K | 282,115 | — | ↗ |
| 2024-07-10 | Coulie Bernard | Director / Officer | S-Sale | D | Common Stock | 38,710 | 11.56 | 447.5K | 482,936 | — | ↗ |
| 2024-07-09 | Ouimette Mike | Officer | A-Award | A | Common Stock | 14,954 | 0.00 | — | 101,700 | — | ↗ |
| 2024-07-09 | Lefebvre Eric | Officer | A-Award | A | Common Stock | 24,063 | 0.00 | — | 225,371 | — | ↗ |
| 2024-07-09 | Hull Hans | Officer | A-Award | A | Common Stock | 19,337 | 0.00 | — | 237,394 | — | ↗ |
| 2024-07-09 | Cummings Keith Lamont | Officer | A-Award | A | Common Stock | 21,313 | 0.00 | — | 293,026 | — | ↗ |
| 2024-07-09 | Coulie Bernard | Director / Officer | A-Award | A | Common Stock | 75,625 | 0.00 | — | 521,646 | — | ↗ |
| 2024-06-13 | Shah Smital | Director | A-Award | A | Common Stock (Right to Buy) | 26,764 | 13.06 | 349.5K | 26,764 | — | ↗ |
| 2024-06-13 | PYOTT DAVID E I | Director | A-Award | A | Common Stock (Right to Buy) | 26,764 | 13.06 | 349.5K | 26,764 | — | ↗ |
| 2024-06-13 | MCCOURT Thomas A | Director | A-Award | A | Common Stock (Right to Buy) | 26,764 | 13.06 | 349.5K | 26,764 | — | ↗ |
| 2024-06-13 | Krognes Steve E. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-06-13 | Knobil Katharine | Director | A-Award | A | Common Stock (Right to Buy) | 26,764 | 13.06 | 349.5K | 26,764 | — | ↗ |
| 2024-06-13 | Huh Hoyoung | Director | A-Award | A | Common Stock (Right to Buy) | 26,764 | 13.06 | 349.5K | 26,764 | — | ↗ |
| 2024-06-13 | Curnutte John T | Director | A-Award | A | Common Stock (Right to Buy) | 26,764 | 13.06 | 349.5K | 26,764 | — | ↗ |
| 2024-06-13 | Cline Darren S | Director | A-Award | A | Common Stock (Right to Buy) | 26,764 | 13.06 | 349.5K | 26,764 | — | ↗ |
| 2024-06-13 | CROWELL GAYLE A | Director | A-Award | A | Common Stock (Right to Buy) | 26,764 | 13.06 | 349.5K | 26,764 | — | ↗ |
| 2024-06-13 | Bruhn Suzanne Louise | Director | A-Award | A | Common Stock (Right to Buy) | 26,764 | 13.06 | 349.5K | 26,764 | — | ↗ |
| 2024-05-02 | Cummings Keith Lamont | Officer | M-Exempt | A | Common Stock | 21,000 | 2.08 | 43.7K | 271,713 | — | ↗ |
| 2024-01-23 | Ouimette Mike | Officer | A-Award | A | Stock Option (Right to Buy) | 63,000 | 17.44 | 1.10M | 63,000 | — | ↗ |
| 2024-01-23 | Lefebvre Eric | Officer | A-Award | A | Stock Option (Right to Buy) | 85,800 | 17.44 | 1.50M | 85,800 | — | ↗ |
| 2024-01-23 | Hull Hans | Officer | A-Award | A | Common Stock | 31,500 | 0.00 | — | 216,569 | — | ↗ |
| 2024-01-23 | Cummings Keith Lamont | Officer | A-Award | A | Common Stock | 55,250 | 0.00 | — | 249,855 | — | ↗ |
| 2024-01-23 | Coulie Bernard | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 256,300 | 17.44 | 4.47M | 256,300 | — | ↗ |
| 2024-01-23 | Cheung Lily | Officer | A-Award | A | Common Stock | 26,000 | 0.00 | — | 26,795 | — | ↗ |
| 2024-01-17 | Ouimette Mike | Officer | S-Sale | D | Common Stock | 5,197 | 17.23 | 89.5K | 55,246 | — | ↗ |
| 2024-01-17 | Lefebvre Eric | Officer | S-Sale | D | Common Stock | 10,295 | 17.23 | 177.4K | 156,920 | — | ↗ |
| 2024-01-17 | Hull Hans | Officer | S-Sale | D | Common Stock | 9,786 | 17.23 | 168.6K | 185,069 | — | ↗ |
| 2024-01-17 | Cummings Keith Lamont | Officer | S-Sale | D | Common Stock | 9,781 | 17.23 | 168.5K | 194,605 | — | ↗ |
| 2024-01-17 | Coulie Bernard | Director / Officer | S-Sale | D | Common Stock | 25,721 | 17.23 | 443.2K | 316,382 | — | ↗ |
| 2023-08-04 | Hull Hans | Officer | M-Exempt | D | Common Stock (Right to Buy) | 8,791 | 2.08 | 18.3K | 31,367 | — | ↗ |
| 2023-08-03 | Hull Hans | Officer | M-Exempt | A | Common Stock | 1,800 | 2.08 | 3.7K | 207,914 | — | ↗ |
| 2023-07-20 | Ouimette Mike | Officer | S-Sale | D | Common Stock | 4,755 | 17.55 | 83.5K | 60,443 | — | ↗ |
| 2023-07-17 | Ouimette Mike | Officer | S-Sale | D | Common Stock | 12,778 | 18.01 | 230.1K | 65,198 | — | ↗ |
| 2023-07-17 | Lefebvre Eric | Officer | S-Sale | D | Common Stock | 22,321 | 18.01 | 402.0K | 167,215 | — | ↗ |
| 2023-07-17 | Hull Hans | Officer | S-Sale | D | Common Stock | 17,937 | 18.01 | 323.0K | 219,183 | — | ↗ |
| 2023-07-17 | Cummings Keith Lamont | Officer | S-Sale | D | Common Stock | 19,771 | 18.01 | 356.1K | 203,999 | — | ↗ |
| 2023-07-17 | Coulie Bernard | Director / Officer | S-Sale | D | Common Stock | 70,150 | 18.01 | 1.26M | 342,103 | — | ↗ |
| 2023-07-14 | Ouimette Mike | Officer | A-Award | A | Common Stock | 27,187 | 0.00 | — | 77,976 | — | ↗ |
| 2023-07-14 | Lefebvre Eric | Officer | A-Award | A | Common Stock | 43,750 | 0.00 | — | 189,536 | — | ↗ |
| 2023-07-14 | Hull Hans | Officer | A-Award | A | Common Stock | 35,156 | 0.00 | — | 237,120 | — | ↗ |
| 2023-07-14 | Cummings Keith Lamont | Officer | A-Award | A | Common Stock | 38,750 | 0.00 | — | 223,770 | — | ↗ |
| 2023-07-14 | Coulie Bernard | Director / Officer | A-Award | A | Common Stock | 137,500 | 0.00 | — | 412,253 | — | ↗ |
| 2023-06-13 | Cummings Keith Lamont | Officer | M-Exempt | A | Common Stock | 30,750 | 2.08 | 64.0K | 185,020 | — | ↗ |
| 2023-06-09 | Cummings Keith Lamont | Officer | M-Exempt | A | Common Stock | 5,800 | 2.08 | 12.1K | 154,270 | — | ↗ |
| 2023-06-07 | Shah Smital | Director | A-Award | A | Stock Option (Right to Buy) | 14,000 | 23.09 | 323.3K | 14,000 | — | ↗ |
| 2023-06-07 | PYOTT DAVID E I | Director | A-Award | A | Stock Option (Right to Buy) | 14,000 | 23.09 | 323.3K | 14,000 | — | ↗ |
| 2023-06-07 | MCCOURT Thomas A | Director | A-Award | A | Stock Option (Right to Buy) | 14,000 | 23.09 | 323.3K | 14,000 | — | ↗ |
| 2023-06-07 | Knobil Katharine | Director | A-Award | A | Stock Option (Right to Buy) | 14,000 | 23.09 | 323.3K | 14,000 | — | ↗ |
| 2023-06-07 | Huh Hoyoung | Director | A-Award | A | Stock Option (Right to Buy) | 14,000 | 23.09 | 323.3K | 14,000 | — | ↗ |
| 2023-06-07 | Curnutte John T | Director | A-Award | A | Stock Option (Right to Buy) | 14,000 | 23.09 | 323.3K | 14,000 | — | ↗ |
| 2023-06-07 | Cline Darren S | Director | A-Award | A | Stock Option (Right to Buy) | 14,000 | 23.09 | 323.3K | 14,000 | — | ↗ |
| 2023-06-07 | CROWELL GAYLE A | Director | A-Award | A | Stock Option (Right to Buy) | 14,000 | 23.09 | 323.3K | 14,000 | — | ↗ |
| 2023-06-07 | Bruhn Suzanne Louise | Director | A-Award | A | Stock Option (Right to Buy) | 14,000 | 23.09 | 323.3K | 14,000 | — | ↗ |
| 2023-04-03 | Ouimette Mike | Officer | S-Sale | D | Common Stock | 2,677 | 26.74 | 71.6K | 50,989 | — | ↗ |
| 2023-03-30 | Ouimette Mike | Officer | S-Sale | D | Common Stock | 4,874 | 26.52 | 129.3K | 53,666 | — | ↗ |
| 2023-03-30 | Lefebvre Eric | Officer | S-Sale | D | Common Stock | 11,245 | 26.52 | 298.2K | 145,786 | — | ↗ |
| 2023-03-30 | Hull Hans | Officer | S-Sale | D | Common Stock | 9,036 | 26.52 | 239.6K | 201,964 | — | ↗ |
| 2023-03-30 | Cummings Keith Lamont | Officer | S-Sale | D | Common Stock | 9,960 | 26.52 | 264.1K | 148,470 | — | ↗ |
| 2023-03-30 | Coulie Bernard | Director / Officer | S-Sale | D | Common Stock | 35,339 | 26.52 | 937.2K | 274,753 | — | ↗ |
| 2023-03-29 | Ouimette Mike | Officer | A-Award | A | Common Stock | 13,593 | 0.00 | — | 58,540 | — | ↗ |
| 2023-03-29 | Lefebvre Eric | Officer | A-Award | A | Common Stock | 21,874 | 0.00 | — | 157,031 | — | ↗ |
| 2023-03-29 | Hull Hans | Officer | A-Award | A | Common Stock | 17,578 | 0.00 | — | 211,000 | — | ↗ |
| 2023-03-29 | Cummings Keith Lamont | Officer | A-Award | A | Common Stock | 19,375 | 0.00 | — | 158,430 | — | ↗ |
| 2023-03-29 | Coulie Bernard | Director / Officer | A-Award | A | Common Stock | 68,749 | 0.00 | — | 310,092 | — | ↗ |
| 2023-03-06 | MCCOURT Thomas A | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 31.11 | 684.4K | 22,000 | — | ↗ |
| 2023-03-06 | Cline Darren S | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 31.11 | 684.4K | 22,000 | — | ↗ |
| 2023-02-03 | Coulie Bernard | Director / Officer | S-Sale | D | Common Stock | 5,262 | 34.08 | 179.3K | 240,112 | — | ↗ |
| 2023-02-02 | Coulie Bernard | Director / Officer | S-Sale | D | Common Stock | 13,395 | 34.13 | 457.1K | 241,717 | — | ↗ |
| 2023-02-01 | Coulie Bernard | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 15,000 | 6.22 | 93.3K | 357,262 | — | ↗ |
| 2023-01-31 | Coulie Bernard | Director / Officer | S-Sale | D | Common Stock | 15,000 | 34.92 | 523.8K | 240,112 | — | ↗ |
| 2023-01-30 | Coulie Bernard | Director / Officer | S-Sale | D | Common Stock | 3,605 | 34.66 | 124.9K | 240,112 | — | ↗ |
| 2023-01-27 | Coulie Bernard | Director | S-Sale | D | Common Stock | 221 | 36.64 | 8.1K | 409,317 | — | ↗ |
| 2023-01-26 | Coulie Bernard | Director | M-Exempt | D | Stock Option (right to buy) | 15,000 | 0.00 | — | 172,380 | — | ↗ |
| 2023-01-25 | Ouimette Mike | Director | A-Award | A | Stock Option (right to buy) | 55,000 | 0.00 | — | 55,000 | — | ↗ |
| 2023-01-25 | Lefebvre Eric | Director / Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 0.00 | — | 80,000 | — | ↗ |
| 2023-01-25 | Hull Hans | Director / Officer | A-Award | A | Common Stock | 54,000 | 0.00 | — | 192,191 | — | ↗ |
| 2023-01-25 | Cummings Keith Lamont | Director / Officer | A-Award | A | Common Stock | 54,000 | 0.00 | — | 138,424 | — | ↗ |
| 2023-01-25 | Coulie Bernard | Director | S-Sale | D | Common Stock | 13,304 | 32.40 | 431.1K | 95,508 | — | ↗ |
| 2023-01-24 | Coulie Bernard | Director | M-Exempt | D | Stock Option (right to buy) | 15,000 | 0.00 | — | 217,380 | — | ↗ |
| 2023-01-23 | Ouimette Mike | Director | S-Sale | D | Common Stock | 20,000 | 34.19 | 683.9K | 5,947 | — | ↗ |
| 2023-01-23 | Lefebvre Eric | Director / Officer | S-Sale | D | Common Stock | 67,500 | 34.48 | 2.33M | 76,926 | — | ↗ |
| 2023-01-23 | Cummings Keith Lamont | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 17,500 | 0.00 | — | 18,198 | — | ↗ |
| 2023-01-23 | Coulie Bernard | Director | M-Exempt | D | Stock Option (right to buy) | 15,000 | 0.00 | — | 232,380 | — | ↗ |
| 2023-01-19 | Cheung Lily | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 123,000 | 0.00 | — | 123,000 | — | ↗ |
| 2023-01-09 | Coulie Bernard | Director | M-Exempt | D | Stock Option (right to buy) | 5,000 | 0.00 | — | 247,380 | — | ↗ |
| 2023-01-06 | Coulie Bernard | Director | M-Exempt | D | Stock Option (right to buy) | 15,000 | 0.00 | — | 252,380 | — | ↗ |
| 2023-01-04 | Coulie Bernard | Director | M-Exempt | A | Common Stock | 15,000 | 2.08 | 31.2K | 108,812 | — | ↗ |
| 2023-01-03 | Coulie Bernard | Director | M-Exempt | D | Stock Option (right to buy) | 15,000 | 0.00 | — | 282,380 | — | ↗ |
| 2022-12-22 | Ouimette Mike | Director | S-Sale | D | Common Stock | 2,928 | 19.38 | 56.7K | 5,947 | — | ↗ |
| 2022-12-22 | Cummings Keith Lamont | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 4,000 | 0.00 | — | 146,097 | — | ↗ |
| 2022-12-20 | Ouimette Mike | Director | S-Sale | D | Common Stock | 4,719 | 19.10 | 90.1K | 8,875 | — | ↗ |
| 2022-12-20 | Lefebvre Eric | Director / Officer | S-Sale | D | Common Stock | 10,887 | 19.10 | 208.0K | 144,426 | — | ↗ |
| 2022-12-20 | Hull Hans | Director / Officer | S-Sale | D | Common Stock | 8,748 | 19.10 | 167.1K | 138,191 | — | ↗ |
| 2022-12-20 | Cummings Keith Lamont | Director / Officer | S-Sale | D | Common Stock | 9,643 | 19.10 | 184.2K | 80,424 | — | ↗ |
| 2022-12-20 | Coulie Bernard | Director | S-Sale | D | Common Stock | 34,212 | 19.10 | 653.5K | 93,812 | — | ↗ |
| 2022-12-19 | Ouimette Mike | Director | A-Award | A | Common Stock | 13,594 | 0.00 | — | 13,594 | — | ↗ |
| 2022-12-19 | Lefebvre Eric | Director / Officer | A-Award | A | Common Stock | 21,876 | 0.00 | — | 155,313 | — | ↗ |
| 2022-12-19 | Hull Hans | Director / Officer | A-Award | A | Common Stock | 17,578 | 0.00 | — | 146,939 | — | ↗ |
| 2022-12-19 | Cummings Keith Lamont | Director / Officer | A-Award | A | Common Stock | 19,375 | 0.00 | — | 90,067 | — | ↗ |
| 2022-12-19 | Coulie Bernard | Director | A-Award | A | Common Stock | 68,751 | 0.00 | — | 128,024 | — | ↗ |
| 2022-11-29 | Third Rock Ventures III, L.P. | Director | J-Other | D | Common Stock | 2,000,000 | 0.00 | — | 1,839,160 | — | ↗ |
| 2022-10-25 | Lefebvre Eric | Officer | S-Sale | D | Common Stock | 5,000 | 25.05 | 125.2K | 133,437 | — | ↗ |
| 2022-09-14 | Knobil Katharine | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 24.23 | 726.9K | 30,000 | — | ↗ |
| 2022-09-12 | Coulie Bernard | Director / Officer | M-Exempt | A | Common Stock | 12,502 | 2.08 | 26.0K | 71,775 | — | ↗ |
| 2022-07-12 | Coulie Bernard | Director / Officer | M-Exempt | A | Common Stock | 12,498 | 2.08 | 26.0K | 71,771 | — | ↗ |
| 2022-07-11 | Lefebvre Eric | Officer | S-Sale | D | Common Stock | 3,000 | 20.00 | 60.0K | 138,436 | — | ↗ |
| 2022-07-11 | Coulie Bernard | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 15,000 | 2.08 | 31.2K | 322,380 | — | ↗ |
| 2022-06-16 | Shah Smital | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-16 | PYOTT DAVID E I | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-16 | Huh Hoyoung | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-16 | Exter Neil | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 6.80 | 102.0K | 15,000 | — | ↗ |
| 2022-06-16 | Curnutte John T | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-16 | CROWELL GAYLE A | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 6.80 | 102.0K | 15,000 | — | ↗ |
| 2022-06-16 | Bruhn Suzanne Louise | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 6.80 | 102.0K | 15,000 | — | ↗ |
| 2022-01-26 | Ouimette Mike | Officer | A-Award | A | Stock Option (right to buy) | 87,000 | 11.86 | 1.03M | 87,000 | — | ↗ |
| 2022-01-26 | Lefebvre Eric | Officer | A-Award | A | Stock Option (right to buy) | 140,000 | 11.86 | 1.66M | 140,000 | — | ↗ |
| 2022-01-26 | Hull Hans | Officer | A-Award | A | Stock Option (right to buy) | 112,500 | 11.86 | 1.33M | 112,500 | — | ↗ |
| 2022-01-26 | Cummings Keith Lamont | Officer | A-Award | A | Stock Option (right to buy) | 124,000 | 11.86 | 1.47M | 124,000 | — | ↗ |
| 2022-01-26 | Coulie Bernard | Director / Officer | A-Award | A | Stock Option (right to buy) | 440,000 | 11.86 | 5.22M | 440,000 | — | ↗ |
| 2021-09-03 | Cummings Keith Lamont | Officer | M-Exempt | D | Stock Option (right to buy) | 20,000 | 2.08 | 41.6K | 150,097 | — | ↗ |
| 2021-06-29 | Shah Smital | Director | A-Award | A | Stock Option (right to buy) | 13,286 | 28.20 | 374.7K | 13,286 | — | ↗ |
| 2021-06-29 | PYOTT DAVID E I | Director | A-Award | A | Stock Option (right to buy) | 13,286 | 28.20 | 374.7K | 13,286 | — | ↗ |
| 2021-06-29 | Huh Hoyoung | Director | A-Award | A | Stock Option (right to buy) | 13,286 | 28.20 | 374.7K | 13,286 | — | ↗ |
| 2021-06-29 | HOMCY CHARLES J | Director | A-Award | A | Stock Option (right to buy) | 13,286 | 28.20 | 374.7K | 13,286 | — | ↗ |
| 2021-06-29 | Exter Neil | Director | A-Award | A | Stock Option (right to buy) | 13,286 | 28.20 | 374.7K | 13,286 | — | ↗ |
| 2021-06-29 | Curnutte John T | Director | A-Award | A | Stock Option (right to buy) | 13,286 | 28.20 | 374.7K | 13,286 | — | ↗ |
| 2021-06-29 | CROWELL GAYLE A | Director | A-Award | A | Stock Option (right to buy) | 13,286 | 28.20 | 374.7K | 13,286 | — | ↗ |
| 2021-06-29 | Bruhn Suzanne Louise | Director | A-Award | A | Stock Option (right to buy) | 13,286 | 28.20 | 374.7K | 13,286 | — | ↗ |
| 2021-06-18 | Lefebvre Eric | Officer | S-Sale | D | Common Stock | 8,750 | 28.62 | 250.4K | 140,830 | — | ↗ |
| 2021-06-14 | Coulie Bernard | Director / Officer | S-Sale | D | Common Stock | 3,757 | 32.98 | 123.9K | 449,560 | — | ↗ |
| 2021-05-26 | Hull Hans | Officer | M-Exempt | A | Common Stock | 4,500 | 2.08 | 9.4K | 125,246 | — | ↗ |
| 2021-05-14 | Coulie Bernard | Director / Officer | S-Sale | D | Common Stock | 503 | 29.28 | 14.7K | 453,317 | — | ↗ |
| 2021-04-14 | Coulie Bernard | Director / Officer | S-Sale | D | Common Stock | 3,500 | 30.33 | 106.2K | 456,817 | — | ↗ |
| 2021-04-13 | Coulie Bernard | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 6,000 | 2.08 | 12.5K | 337,380 | — | ↗ |
| 2021-03-18 | Lefebvre Eric | Officer | S-Sale | D | Common Stock | 11,365 | 39.38 | 447.5K | 150,715 | — | ↗ |
| 2021-03-15 | Coulie Bernard | Director / Officer | S-Sale | D | Common Stock | 1,322 | 38.03 | 50.3K | 462,495 | — | ↗ |
| 2021-03-05 | Cummings Keith Lamont | Officer | M-Exempt | D | Stock Option (right to buy) | 20,000 | 2.08 | 41.6K | 170,097 | — | ↗ |
| 2021-02-16 | Coulie Bernard | Director / Officer | S-Sale | D | Common Stock | 2,100 | 32.87 | 69.0K | 464,017 | — | ↗ |
| 2021-01-23 | Ouimette Mike | Officer | A-Award | A | Stock Option (right to buy) | 15,520 | 26.50 | 411.3K | 15,520 | — | ↗ |
| 2021-01-23 | Lefebvre Eric | Officer | A-Award | A | Stock Option (right to buy) | 73,250 | 26.50 | 1.94M | 73,250 | — | ↗ |
| 2021-01-23 | Hull Hans | Officer | A-Award | A | Stock Option (right to buy) | 62,250 | 26.50 | 1.65M | 62,250 | — | ↗ |
| 2021-01-23 | Howes Barbara | Officer | A-Award | A | Stock Option (right to buy) | 42,500 | 26.50 | 1.13M | 42,500 | — | ↗ |
| 2021-01-23 | Cummings Keith Lamont | Officer | A-Award | A | Stock Option (right to buy) | 74,250 | 26.50 | 1.97M | 74,250 | — | ↗ |
| 2021-01-23 | Coulie Bernard | Director / Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 26.50 | 6.63M | 250,000 | — | ↗ |
| 2021-01-14 | Coulie Bernard | Director / Officer | S-Sale | D | Common Stock | 2,870 | 26.20 | 75.2K | 467,947 | — | ↗ |
| 2021-01-12 | PYOTT DAVID E I | Director | A-Award | A | Stock Option (right to buy) | 26,573 | 27.71 | 736.3K | 26,573 | — | ↗ |
| 2020-12-30 | Hull Hans | Officer | M-Exempt | A | Common Stock | 3,500 | 2.08 | 7.3K | 120,746 | — | ↗ |
| 2020-12-21 | Cummings Keith Lamont | Officer | M-Exempt | D | Stock Option (right to buy) | 4,500 | 2.08 | 9.4K | 190,097 | — | ↗ |
| 2020-12-18 | Lefebvre Eric | Officer | S-Sale | D | Common Stock | 6,788 | 26.17 | 177.6K | 167,792 | — | ↗ |
| 2020-12-14 | Coulie Bernard | Director / Officer | S-Sale | D | Common Stock | 3,163 | 27.32 | 86.4K | 471,154 | — | ↗ |
| 2020-12-01 | Cummings Keith Lamont | Officer | M-Exempt | D | Stock Option (right to buy) | 7,143 | 6.22 | 44.4K | 35,698 | — | ↗ |
| 2020-10-09 | Ouimette Mike | Officer | A-Award | A | Stock Option (right to buy) | 108,240 | 24.32 | 2.63M | 108,240 | — | ↗ |
| 2020-10-01 | Ouimette Mike | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-05 | Third Rock Ventures III, L.P. | 10% Owner | C-Conversion | A | Common Stock | 5,559,440 | 0.00 | — | 5,839,160 | — | ↗ |
| 2020-06-05 | Redmile Group, LLC | 10% Owner | C-Conversion | A | Common Stock | 1,910,657 | 0.00 | — | 1,910,657 | — | ↗ |
| 2020-06-05 | Hull Hans | Officer | C-Conversion | A | Common Stock | 5,079 | 0.00 | — | 117,246 | — | ↗ |
| 2020-06-05 | Huh Hoyoung | Director | C-Conversion | A | Series A Preferred Stock | 1,000,000 | 0.00 | — | 0 | — | ↗ |
| 2020-06-05 | Howes Barbara | Officer | C-Conversion | D | Series C Preferred Stock | 27,322 | 0.00 | — | 0 | — | ↗ |
| 2020-06-05 | Exter Neil | Director | C-Conversion | D | Series A Preferred Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-05 | Cummings Keith Lamont | Officer | C-Conversion | D | Series C Preferred Stock | 27,322 | 0.00 | — | 0 | — | ↗ |
| 2020-06-05 | Coulie Bernard | Director / Officer | C-Conversion | D | Series B Preferred Stock | 181,594 | 0.00 | — | 0 | — | ↗ |
| 2020-06-02 | Third Rock Ventures III, L.P. | 10% Owner | — | I | Series A Preferred Stock | 2,132,867 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
61.91M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Bernard Coulie, M.D., Ph.D., M.B.A. President, Chief Executive Officer and Director | 682.0K | — | 1.81M | 2.71M | 204.6K | 52.3K | 5.46M | 82.81% | ↗ |
| 2 | 2025 | Éric Lefebvre, M.D. Former Chief Medical Officer | 571.9K | 215.6K | 508.5K | 762.4K | — | 666.5K | 2.72M | 46.64% | ↗ |
| 3 | 2025 | Keith Cummings, M.D., M.B.A. Chief Financial Officer | 503.9K | 201.6K | 631.1K | 946.1K | 100.8K | 14.0K | 2.40M | 65.79% | ↗ |
| 4 | 2025 | Minnie Kuo Chief Operating Officer | 470.7K | 188.3K | 307.5K | 460.9K | 103.6K | 11.9K | 1.54M | 49.80% | ↗ |
| 5 | 2024 | Bernard Coulie, M.D., Ph.D., M.B.A. President, Chief Executive Officer and Director | 640.8K | — | 2.23M | 3.30M | 384.5K | 53.3K | 6.61M | 83.69% | ↗ |
| 6 | 2024 | Keith Cummings, M.D., M.B.A. Chief Financial Officer | 484.5K | — | 963.6K | 1.42M | 213.2K | 15.4K | 3.10M | 77.00% | ↗ |
| 7 | 2024 | Éric Lefebvre, M.D. Chief Medical Officer | 520.3K | — | 748.2K | 1.11M | 228.9K | 13.1K | 2.62M | 70.85% | ↗ |
| 8 | 2024 | Éric Lefebvre, M.D. Former Chief Medical Officer | 520.3K | — | 748.2K | 1.11M | 228.9K | 13.1K | 2.62M | 70.85% | ↗ |
| 9 | 2024 | Hans Hull, J.D. Chief Business Officer | 444.4K | — | 549.4K | 811.4K | 195.5K | 14.6K | 2.02M | 67.52% | ↗ |
| 10 | 2024 | Mike Ouimette, J.D. Chief Legal and Compliance Officer and Secretary | 442.9K | — | 549.4K | 811.4K | 177.2K | 13.4K | 1.99M | 68.24% | ↗ |
| 11 | 2023 | Bernard Coulie, M.D., Ph.D., MBA President, Chief Executive Officer and Director | 610.3K | — | 5.07M | 5.10M | 335.7K | 51.0K | 11.17M | 91.07% | ↗ |
| 12 | 2023 | Bernard Coulie, M.D., Ph.D., M.B.A. President, Chief Executive Officer and Director | 610.3K | — | 5.07M | 5.10M | 335.7K | 51.0K | 11.17M | 91.07% | ↗ |
| 13 | 2023 | Éric Lefebvre, M.D. Chief Medical Officer | 500.3K | — | 1.98M | 1.98M | 220.1K | 14.0K | 4.69M | 84.33% | ↗ |
| 14 | 2023 | Keith Cummings, M.D., MBA Chief Financial Officer | 452.8K | — | 1.87M | 1.88M | 217.3K | 14.0K | 4.44M | 84.59% | ↗ |
| 15 | 2023 | Keith Cummings, M.D., M.B.A. Chief Financial Officer | 452.8K | — | 1.87M | 1.88M | 217.3K | 14.0K | 4.44M | 84.59% | ↗ |
| 16 | 2023 | Hans Hull, J.D. Chief Business Officer | 427.3K | — | 1.87M | 1.88M | 170.9K | 4.3K | 4.36M | 86.17% | ↗ |
| 17 | 2023 | Mike Ouimette, J.D. General Counsel and Corporate Secretary | 425.9K | — | 1.35M | 1.36M | 170.4K | 9.8K | 3.32M | 81.73% | ↗ |
| 18 | 2023 | Mike Ouimette, J.D. Chief Legal and Compliance Officer and Secretary | 425.9K | — | 1.35M | 1.36M | 170.4K | 9.8K | 3.32M | 81.73% | ↗ |
| 19 | 2022 | Bernard Coulie, M.D., Ph.D., M.B.A. President, Chief Executive Officer and Director | 586.8K | — | 6.42M | 3.44M | 440.0K | 32.8K | 10.93M | 90.30% | ↗ |
| 20 | 2022 | Bernard Coulie, M.D., Ph.D. President, Chief Executive Officer and Director | 586.8K | — | 6.42M | 3.44M | 440.0K | 32.8K | 10.93M | 90.30% | ↗ |
| 21 | 2022 | Bernard Coulie, M.D., Ph.D., MBA President, Chief Executive Officer and Director | 586.8K | — | 6.42M | 3.44M | 440.0K | 32.8K | 10.93M | 90.30% | ↗ |
| 22 | 2022 | Éric Lefebvre, M.D. Chief Medical Officer | 481.1K | — | 2.04M | 1.10M | 269.4K | 13.0K | 3.90M | 80.44% | ↗ |
| 23 | 2022 | Keith Cummings, M.D., MBA Chief Financial Officer | 427.2K | — | 1.81M | 970.6K | 222.1K | 13.0K | 3.44M | 80.76% | ↗ |
| 24 | 2022 | Keith Cummings, M.D., M.B.A. Chief Financial Officer | 427.2K | — | 1.81M | 970.6K | 222.1K | 13.0K | 3.44M | 80.76% | ↗ |
| 25 | 2022 | Hans Hull, J.D. Chief Business Officer | 407.0K | — | 1.64M | 880.6K | 211.6K | 13.0K | 3.15M | 79.98% | ↗ |
| 26 | 2022 | Mike Ouimette, J.D. General Counsel and Corporate Secretary | 398.0K | — | 1.27M | 681.0K | 191.0K | 2.0K | 2.54M | 76.75% | ↗ |
| 27 | 2022 | Mike Ouimette, J.D. Chief Legal and Compliance Officer and Secretary | 398.0K | — | 1.27M | 681.0K | 191.0K | 2.0K | 2.54M | 76.75% | ↗ |
| 28 | 2021 | Bernard Coulie, M.D., Ph.D., MBA President, Chief Executive Officer and Director | 556.2K | — | — | 4.30M | 321.2K | 42.2K | 5.22M | 82.39% | ↗ |
| 29 | 2021 | Bernard Coulie, M.D., Ph.D. President, Chief Executive Officer and Director | 556.2K | — | — | 4.30M | 321.2K | 42.2K | 5.22M | 82.39% | ↗ |
| 30 | 2021 | Éric Lefebvre, M.D. Chief Medical Officer | 456.0K | — | — | 1.26M | 246.2K | 11.6K | 1.97M | 63.84% | ↗ |
| 31 | 2021 | Keith Cummings, M.D., MBA Chief Financial Officer | 401.7K | — | — | 1.28M | 192.8K | 11.6K | 1.88M | 67.82% | ↗ |
| 32 | 2021 | Hans Hull, J.D. Chief Business Officer | 385.7K | — | — | 1.07M | 185.2K | 11.6K | 1.65M | 64.78% | ↗ |
| 33 | 2021 | Barbara Howes, MBA Former Chief Human Resources Officer | 254.5K | — | — | 731.3K | — | 10.1K | 995.9K | 73.43% | ↗ |
| 34 | 2021 | Mike Ouimette, J.D. General Counsel and Corporate Secretary | 362.7K | — | — | 267.1K | 174.1K | 1.2K | 805.0K | 33.17% | ↗ |
| 35 | 2020 | Bernard J. Coulie, M.D., Ph.D. Chief Executive Officer | 499.0K | — | — | 1.50M | 351.0K | 45.2K | 2.39M | 62.57% | ↗ |
| 36 | 2020 | Bernard Coulie, M.D., Ph.D. President, Chief Executive Officer and Director | 499.0K | — | — | 1.50M | 351.0K | 45.2K | 2.39M | 62.57% | ↗ |
| 37 | 2020 | Éric Lefebvre, M.D. Chief Medical Officer | 425.5K | — | — | 288.6K | 209.2K | 11.4K | 874.7K | 33.00% | ↗ |
| 38 | 2020 | Hans Hull, J.D. Chief Business Officer | 372.5K | — | — | 279.0K | 177.0K | 11.4K | 839.9K | 33.22% | ↗ |
| 39 | 2019 | Bernard J. Coulie, M.D., Ph.D. Chief Executive Officer | 428.1K | 2.0K | — | 1.67M | 219.2K | 49.9K | 2.37M | 70.53% | ↗ |
| 40 | 2019 | Bernard Coulie, M.D., Ph.D. President, Chief Executive Officer and Director | 428.1K | 2.0K | — | 1.67M | 219.2K | 49.9K | 2.37M | 70.53% | ↗ |
| 41 | 2019 | Hans Hull, J.D. Chief Business Officer | 355.1K | 75.0K | — | 268.6K | 136.4K | 11.2K | 846.3K | 31.73% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bernard Coulie | President, Chief Executive Officer & Director | 938.9K | — |
| Keith Lamont Cummings | Chief Financial Officer | 820.2K | — |
| Minnie Kuo | Chief Operating Officer | 774.5K | female |
| Delphine Imbert | Chief Technical Officer | — | female |
| Hal Chapman | Scientific Founder & Member of Scientific Advisory Board | — | male |
| Christopher S. Keenan | Vice President of Investor Relations & Corporate Communications | — | male |
| Lily Cheung | Chief Human Resources Officer | — | female |
| Monica Sandberg | Vice President, Regulatory & Compliance | — | — |
| Dean Sheppard | Scientific Founder & Member of Scientific Advisory Board | — | male |
| Rik Derynck | Scientific Founder & Member of Scientific Advisory Board | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PLRX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
